Hims & Hers stock fall to a 12-month low after Novo said it's $49 Wegovy pill copy was "illegal"
In this article
The stock of Hims & Hers
dropped in premarket trading early Friday after a legal threat from Novo Nordisk
The online teleheath company announced on Thursday plans to launch a cheaper, copycat version of Novo’s
weight loss pill, prompting Novo to take legal action.
Novo Nordisk and Eli Lilly fell after Hims & Hers said it will offer a copy of the Wegovy pill for $49, far less than the $149…
Novo Nordisk said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false…
Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell…
Shares of Hims & Hers jumped as much as 55% Monday after Novo Nordisk announced it is dropping its lawsuit over Ozempic and…
Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.
In June, Hims & Hers shares tumbled more than 30% after a short-lived collaboration with Novo Nordisk fell apart.
Novo Nordisk sues Hims & Hers over copycat weight-loss drugs
